T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties.

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Abstract Text:

Yang Li,Zhulun Wang,Noboru Furukawa,Patrick Escaron,Jennifer Weiszmann,Gary Lee,Michelle Lindstrom,Jinsong Liu,Xiaohong Liu,Haoda Xu,Olga Plotnikova,Vidya Prasad,Nigel Walker,R Marc Learned,Jin-Long Chen,

The nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma) plays central roles in adipogenesis and glucose homeostasis and is the molecular target for the thiazolidinedione (TZD) class of antidiabetic drugs. Activation of PPARgamma by TZDs improves insulin sensitivity; however, this is accompanied by the induction of several undesirable side effects. We have identified a novel synthetic PPARgamma ligand, T2384, to explore the biological activities associated with occupying different regions of the receptor ligand-binding pocket. X-ray crystallography studies revealed that T2384 can adopt two distinct binding modes, which we have termed "U" and "S", interacting with the ligand-binding pocket of PPARgamma primarily via hydrophobic contacts that are distinct from full agonists. The different binding modes occupied by T2384 induced distinct patterns of coregulatory protein interaction with PPARgamma in vitro and displayed unique receptor function in cell-based activity assays. We speculate that these unique biochemical and cellular activities may be responsible for the novel in vivo profile observed in animals treated systemically with T2384. When administered to diabetic KKAy mice, T2384 rapidly improved insulin sensitivity in the absence of weight gain, hemodilution, and anemia characteristics of treatment with rosiglitazone (a TZD). Moreover, upon coadministration with rosiglitazone, T2384 was able to antagonize the side effects induced by rosiglitazone treatment alone while retaining robust effects on glucose disposal. These results are consistent with the hypothesis that interactions between ligands and specific regions of the receptor ligand-binding pocket might selectively trigger a subset of receptor-mediated biological responses leading to the improvement of insulin sensitivity, without eliciting less desirable responses associated with full activation of the receptor. We suggest that T2384 may represent a prototype for a novel class of PPARgamma ligand and, furthermore, that molecules sharing some of these properties would be useful for treatment of type 2 diabetes.

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Publishing Authors By Initials

Y Li,Z Wang,N Furukawa,P Escaron,J Weiszmann,G Lee,M Lindstrom,J Liu,X Liu,H Xu,O Plotnikova,V Prasad,N Walker,RM Learned,JL Chen,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of biological chemistry

VOLUME: 283

Page Numbers: 9168-76

Journal Abbreviation:

ISSN: 0021-9258

DAY: 7

MONTH: 02

YEAR: 2008

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985121

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Biol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor {gamma} Binding Properties Related Publications

• A new function of BMP4: dual role for BMP4 in regulation of Sonic hedgehog expression in the mouse tooth germ.
• An experimental study of anti-angiogenesis with recombinant human kringle 5.
• Application of Nd-Yag laser for gingivoplasty during orthodontic treatment.
• Clinical study of alveolar vertical distraction osteogenesis for implant.
• Enzyme-linked immunosorbent assay for the determination of p21-activated kinase activity.
• Hemorheology and expression of neutrophil adhesion molecules CD18 and CD62L in pancreatic microcirculation of Caerulein induced experimental acute pancreatitis.
• Lack of effect of dietary alpha-tocopherol on chemically induced hepatocarcinogenesis in rats.
• Prostaglandin E2 is involved in the increase of cytochrome P-450 2B1 expression by alpha-tocopheryl succinate in primary rat hepatocytes in the presence of phenobarbital.
• Rescue of cleft palate in Msx1-deficient mice by transgenic Bmp4 reveals a network of BMP and Shh signaling in the regulation of mammalian palatogenesis.
• Transgenically ectopic expression of Bmp4 to the Msx1 mutant dental mesenchyme restores downstream gene expression but represses Shh and Bmp2 in the enamel knot of wild type tooth germ.
• [A study on apoptosis and activity of SAPK/JNK in adrenocortical cells induced by cadmium chloride]
• [A study on central zone contour of tooth-crown vesticular surface among young people with normal occlusion]
• [Bone-inducing activity of human bone morphogenetic protein-2 102 peptide]
• [Comparative effects of tensiomin and sodium dimercaptosulphonate on the serum sulfydryl and anticopper of the patients with Wilson's disease]
• [Effects of fluoride on the expression of c-fos and c-jun genes and cell proliferation of rat osteoblasts]
• [Establishment of EBV-immortalized lymphoblast cell lines from three Chinese Fanconi anemia patient and their subtyping]
• [Experimental methods for mechanically stimulating the cells in vitro]
• [Focal adhesion kinase]
• [GATA-2 gene expression in leukemia patients and its significance]
• [Genetic polymorphisms of cytochrome P450 1A1 and susceptibility of early-onset Parkinson's disease]
• [Influence of chemotherapy on hematopoietic microenvironment and effect of autologous bone marrow stromal cell infusion on the recovery of hematopoiesis after chemotherapy]
• [Influence of the stratum corneum and dermis of the skin on the percutaneous absorption of fluorouracil delivered through skin patch]
• [Isolation, cultivation and identification of neural stem cell from human embryonic CNS]
• [Melanoma antigen-3 expression in human hepatocellular carcinoma]
• [Novel full-length cDNA cloning from normal adrenal gland and pheochromocytoma and functional prediction]
• [Preparation and application of a new chloromethylstyrene encapsulated silica single anion column]
• [Study on the intestinal microbial colonization resistance in patients with chronic severe hepatitis]
• [Synergetic transactivating functions of HCV core and truncated HBV middle surface protein]
• [Telomerase activity and cellular apoptosis of bladder cancers]
• [The apolipoprotein E gene polymorphism in children with steroid-resistant idiopathic nephrotic syndrome]